Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus

Status Completed

Clinical Trial Summary

Radiofrequency ablation (RFA) is a mainstay of treatment for patients who have Barrett's esophagus (BE) with dysplasia. For unclear reasons, Barrett's esophagus recurs after successful RFA treatment in approximately 1/3 of patients. The aim of this study is to characterize the healing process of the esophageal mucosa, histologically and at the molecular level, after RFA for non-dysplastic and dysplastic Barrett's esophagus.

Clinical Trial Description

Radiofrequency ablation (RFA) is a mainstay of treatment for patients who have Barrett's esophagus (BE) with dysplasia. For unclear reasons, Barrett's esophagus recurs after successful RFA treatment in approximately 1/3 of patients. Little is known of how the esophagus heals after RFA treatment, and a better understanding of this healing process might provide insights into how to prevent Barrett's metaplasia from recurring after successful ablation. The aim of this study is to characterize the healing process of the esophageal mucosa, histologically and at the molecular level, after RFA for non-dysplastic and dysplastic Barrett's esophagus. Patients with Barrett's esophagus will undergo surveillance endoscopy with biopsy. This will be followed by RFA treatment of the BE and follow up endoscopy will be performed 1, 2, and 4 weeks after RFA. Healing at each time point will be assessed endoscopically, and molecular markers related to healing will be studied. Stem cell expression markers, immune cells and markers of epithelial-mesenchymal transition will be compared with baseline expression for each patient. Protocol has been modified to provide a collaborative effort between the Dallas VAMC and Baylor Scott & White Medical Center in Dallas, TX. Veteran participants electing to participate will receive initial screening and endoscopy at the Dallas VAMC and will continue with RFA and follow-up endoscopies at Baylor. An identical protocol has been approved at Baylor Scott & White Medical center. Patients who are screened and enrolled at Baylor will receive all treatments at that location. ;

Study Design

Related Conditions & MeSH terms

Barrett Esophagus

Clinical Trial Details

NCT number	NCT02688114
Study type	Interventional
Source	Dallas VA Medical Center
Contact
Status	Completed
Phase	N/A
Start date	October 18, 2017
Completion date	January 29, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03554356` - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)	N/A
Completed	`NCT03015389` - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Completed	`NCT03434834` - OCT Pilot in Esophagus	N/A
Terminated	`NCT04642690` - Nitrates and IL-8 in Barrett's Esophagus
Completed	`NCT03468634` - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy	N/A
Recruiting	`NCT02310230` - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy	N/A
Completed	`NCT00217087` - Endoscopic Therapy of Early Cancer in Barretts Esophagus	Phase 2
Completed	`NCT02284802` - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy	N/A
Recruiting	`NCT05530343` - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance	N/A
Active, not recruiting	`NCT04151524` - Classification of Adenocarcinoma of the Esophagogastric Junction
Completed	`NCT00955019` - Novel Method of Surveillance in Barrett's Esophagus	Phase 2
Terminated	`NCT00386594` - Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus	N/A
Completed	`NCT00576498` - Novel Imaging Techniques in Barrett's Esophagus	N/A
Recruiting	`NCT06071845` - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples	N/A
Completed	`NCT02560623` - A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus	N/A
Recruiting	`NCT05056051` - Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus	N/A
Recruiting	`NCT04001478` - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Completed	`NCT03859557` - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed	`NCT04587310` - Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study
Recruiting	`NCT05107219` - GCC Agonist Signal in the Small Intestine	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.